रैंकिंग पर वापस जाएं

Penumbra, Inc. (PEN)

NEUTRAL
HealthcareMedical DevicesUnited States

Fundamental

67

मूल्य

$323.90

मार्केट कैप

$12.79B

भाग 1 · कंपनी का मूल्य कितना है

अवलोकन

Penumbra designs and manufactures devices that remove blood clots from inside the body without open surgery, threading a catheter through a blood vessel to pull the clot out or suck it away. Its products treat conditions such as ischemic stroke, pulmonary embolism and acute limb ischemia. A second, related line of products helps physicians access blood vessels and block off unwanted ones, such as before a tumor is removed. It sells to hospitals and clinics in over 100 countries.

यह पैसा कैसे कमाती है

Penumbra sells physical devices — catheters, aspiration systems and related disposables — to hospitals, which use them one procedure at a time. Because each stroke, clot or vascular case consumes a new device, revenue grows with the number of procedures performed rather than through subscriptions, and it depends on hospitals adopting Penumbra's technology over rival devices, on regulatory clearance for new products, and on reimbursement from insurers and public health systems that pay for the procedure.

सेगमेंट के अनुसार राजस्व

Thrombectomy67.5%

Devices that remove blood clots to treat pulmonary embolism, deep vein thrombosis, acute limb ischemia, ischemic stroke and coronary disease.

Embolization and Access32.5%

Devices that help physicians access blood vessels and selectively block off unwanted ones, used in a range of vascular procedures.

प्रतिस्पर्धी बढ़त (Moat)

पेटेंट और लाइसेंस · संकीर्ण

Penumbra's devices are protected by patents on their specific mechanical and aspiration designs, and any new device must clear a lengthy regulatory approval process before it can be sold, which slows down copycats. That said, the field has several capable competitors building similar clot-removal technology, so the protection is real but not close to exclusive.

मांग को क्या चलाता है

डिफेंसिव

Penumbra's core products treat medical emergencies such as stroke, pulmonary embolism and limb-threatening blood clots, procedures that hospitals perform regardless of the economic climate because delaying them risks death or permanent disability. Demand is therefore driven mainly by disease incidence, physician adoption of minimally invasive techniques, and hospital budgets for equipment, not by discretionary consumer spending.

प्रमुख जोखिम

  • Lengthy and uncertain regulatory approval — The company operates under stringent domestic and foreign medical device regulations, and delays or failures in obtaining approval for new or modified products can push back launches and revenue.
  • Product liability litigation — As a maker of devices used in life-critical procedures, the company faces product liability claims and lawsuits seeking compensatory and punitive damages over alleged device failures or injuries.
  • Restrictions on off-label promotion — Regulators actively enforce rules against promoting a device for uses it was not approved for, and a violation can bring substantial monetary penalties or criminal prosecution.
  • Mandatory adverse event reporting — Medical device reporting rules require the company to notify regulators whenever it learns a device may have caused or contributed to a death or serious injury, which can trigger investigations or recalls.

खरीदने के पक्ष में तर्क

Buyers argue that thrombectomy is still replacing older, less effective treatments for stroke and clot-related emergencies, that Penumbra's revenue keeps growing faster than the market, and that its second embolization and access line adds a further avenue for growth beyond its original thrombectomy business.

बेचने के पक्ष में तर्क

Sellers fear that well-funded competitors are developing similar clot-removal technology, that a single unfavorable regulatory finding or product-liability case could damage both revenue and reputation quickly, and that a business built on emergency procedures leaves little room to grow through pricing.

वित्त वर्ष 2025 के सेगमेंट आंकड़ेस्रोत: Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Written by the editors, published on 18 अगस्त 2026

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

बैलेंस शीट और तरलता

राजस्व

$1.50B

पिछले 12 महीने (30/6/2026 तक)

शुद्ध आय

$161M

पिछले 12 महीने (30/6/2026 तक)

Free Cash Flow

$175M

कुल इक्विटी

$1.43B

कुल देनदारियाँ

$399M

Current Ratio

5.75

Interest Coverage

144.33

Debt/EBITDA

1.03

Earnings Per Share

राजस्व और शुद्ध आय

Free Cash Flow

आय विवरण

ऐतिहासिक विवरण

समय के साथ मार्जिन

समय के साथ ऋण

ऋण कितना भारी है

वृद्धि तालिका

वृद्धि — राजस्व

Fair Value अनुमान

अधिक मूल्यांकित

Fair Value

$238.51

वर्तमान मूल्य

$323.90

Margin of Safety

-35.8%

Fair Value सीमा

$155.03 - $321.99

अनुमान विधियाँ

Analyst Target:$361.83
DCF:$106.51
PE-based:$280.42
Graham Growth:$66.10
EPV:$44.76
विश्लेषक सहमति:रोकें (6B / 14H / 0S)
अंतिम Earnings सरप्राइज़:-26.59%

मूल्यांकन मेट्रिक्स

P/E Ratio

79.55

ROE

12.4%

P/B Ratio

8.33

P/FCF

59.06

Gross Margin

67.8%

ROIC

8.5%

लाभप्रदता Radar

Value Creation (Economic Moat)

ROIC

8.5%

WACC

8.2%

ROIC − WACC

+0.3 pp

ROIC is roughly in line with the cost of capital — the company is barely covering its capital cost.

Fundamental विश्लेषण मानदंड

पास (18)

  • EPS shows upward trend
  • EPS CAGR 33.58%
  • Price CAGR 17.69%
  • ROIC 8.5%
  • Gross Margin 67.8%
  • Debt/Equity ratio
  • Operating Margin 12.4%
  • Positive Free Cash Flow
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • ROE 11.1%
  • Revenue Growth 5Y 20.2%
  • Earnings Quality (OCF/NI) 1.73
  • Share Dilution 1.0%
  • Piotroski F-Score 8/9

फेल (8)

  • P/FCF 59.06
  • P/B Ratio 8.33
  • CapEx intensity
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Analyst Consensus 30% Buy
  • Earnings Surprise avg -10.5%
  • Net Margin Trend 10.7% vs 11.5%

अनुपलब्ध (2)

  • Dividend Payout NaN%
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-Score

8/9

मजबूत वित्तीय स्वास्थ्य

score
criteria

Earnings गुणवत्ता

1.73

उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित

शेयर Dilution

1.0%

शेयर संख्या स्थिर है

प्रशासन

कार्यकारी टीम

नामपदआयु
Mr. Adam Elsesser J.D.Co-Founder, Chairman & CEO63
Ms. Shruthi NarayanPresident40
Dr. Arani Bose M.D.Co-Founder & Director63
Ms. Maggie S. YuenChief Financial Officer53
Mr. Lambert ShiuChief Accounting Officer45
Ms. Johanna Roberts J.D.Executive VP, General Counsel & Secretary53
Mr. Ben SorciExecutive Vice President of Operations-
Mr. Pankaj TiwariExecutive VP & Chief Information Officer-

Audit जोखिम

7

बोर्ड जोखिम

5

मुआवजा जोखिम

7

शेयरधारक अधिकार जोखिम

4

भाग 2 · कीमत और खरीदने का समय

यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।

Latest News

Recent headlines for PEN, sourced from Markets Gazette.

  • 2/25/2026NEUTRAL
    Penumbra Q4 Earnings Assessment

    The financial community is keenly awaiting the assessment of Penumbra Inc.'s fourth-quarter earnings. While specific details from this analysis have not yet been released, investor attention remains high, given the critical importance of such reports in gauging the medical device company's financial health and future prospects. Q4 performance is particularly crucial for Penumbra, operating in a competitive medical technology market where innovation and clinical outcomes drive growth. Analysts will be closely scrutinizing key metrics such as revenue figures, profit margins, and forward-looking guidance for the upcoming year, seeking indications of the company's ability to sustain its growth trajectory and navigate industry challenges. The full disclosure of these results will provide clear direction for the stock.

via Markets Gazette

Disclaimer

यह प्लेटफ़ॉर्म केवल शैक्षिक उद्देश्यों के लिए है। यह कोई वित्तीय, निवेश, या ट्रेडिंग सलाह नहीं देता। सभी स्कोर, मूल्यांकन, और संकेत सार्वजनिक रूप से उपलब्ध डेटा के स्वचालित विश्लेषण पर आधारित हैं जो अधूरे या गलत हो सकते हैं। निवेश निर्णय लेने से पहले हमेशा अपना शोध करें और एक योग्य वित्तीय सलाहकार से परामर्श लें।

निर्मित द्वारा CODEPRESS s.r.l.